-
Something wrong with this record ?
GABBR1 monoallelic de novo variants linked to neurodevelopmental delay and epilepsy
ML. Cediel, M. Stawarski, X. Blanc, L. Nosková, M. Magner, K. Platzer, J. Gburek-Augustat, D. Baldridge, JN. Constantino, E. Ranza, B. Bettler, SE. Antonarakis
Language English Country United States
Document type Journal Article
NLK
Cell Press Free Archives
from 1997-01-01 to 6 months ago
Free Medical Journals
from 1949 to 6 months ago
PubMed Central
from 1949 to 6 months ago
Europe PubMed Central
from 1949 to 6 months ago
Open Access Digital Library
from 2005-01-01
- MeSH
- Epilepsy * genetics MeSH
- gamma-Aminobutyric Acid metabolism MeSH
- HEK293 Cells MeSH
- Humans MeSH
- Nervous System Malformations * MeSH
- Intellectual Disability * genetics MeSH
- Neurodevelopmental Disorders * genetics MeSH
- Receptors, GABA-B * genetics MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
GABAB receptors are obligatory heterodimers responsible for prolonged neuronal inhibition in the central nervous system. The two receptor subunits are encoded by GABBR1 and GABBR2. Variants in GABBR2 have been associated with a Rett-like phenotype (MIM: 617903), epileptic encephalopathy (MIM: 617904), and milder forms of developmental delay with absence epilepsy. To date, however, no phenotypes associated with pathogenic variants of GABBR1 have been established. Through GeneMatcher, we have ascertained four individuals who each have a monoallelic GABBR1 de novo non-synonymous variant; these individuals exhibit motor and/or language delay, ranging from mild to severe, and in one case, epilepsy. Further phenotypic features include varying degrees of intellectual disability, learning difficulties, autism, ADHD, ODD, sleep disorders, and muscular hypotonia. We functionally characterized the four de novo GABBR1 variants, p.Glu368Asp, p.Ala397Val, p.Ala535Thr, and p.Gly673Asp, in transfected HEK293 cells. GABA fails to efficiently activate the variant receptors, most likely leading to an increase in the excitation/inhibition balance in the central nervous system. Variant p.Gly673Asp in transmembrane domain 3 (TMD3) renders the receptor completely inactive, consistent with failure of the receptor to reach the cell surface. p.Glu368Asp is located near the orthosteric binding site and reduces GABA potency and efficacy at the receptor. GABA exhibits normal potency but decreased efficacy at the p.Ala397Val and p.Ala535Thr variants. Functional characterization of GABBR1-related variants provides a rationale for understanding the severity of disease phenotypes and points to possible therapeutic strategies.
Institute of Human Genetics University of Leipzig Medical Center Leipzig Germany
Medigenome Swiss Institute of Genomic Medicine 1207 Geneva Switzerland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22033119
- 003
- CZ-PrNML
- 005
- 20230131151207.0
- 007
- ta
- 008
- 230120s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ajhg.2022.08.010 $2 doi
- 035 __
- $a (PubMed)36103875
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Cediel, Maria Lucia $u Medigenome, Swiss Institute of Genomic Medicine, 1207 Geneva, Switzerland
- 245 10
- $a GABBR1 monoallelic de novo variants linked to neurodevelopmental delay and epilepsy / $c ML. Cediel, M. Stawarski, X. Blanc, L. Nosková, M. Magner, K. Platzer, J. Gburek-Augustat, D. Baldridge, JN. Constantino, E. Ranza, B. Bettler, SE. Antonarakis
- 520 9_
- $a GABAB receptors are obligatory heterodimers responsible for prolonged neuronal inhibition in the central nervous system. The two receptor subunits are encoded by GABBR1 and GABBR2. Variants in GABBR2 have been associated with a Rett-like phenotype (MIM: 617903), epileptic encephalopathy (MIM: 617904), and milder forms of developmental delay with absence epilepsy. To date, however, no phenotypes associated with pathogenic variants of GABBR1 have been established. Through GeneMatcher, we have ascertained four individuals who each have a monoallelic GABBR1 de novo non-synonymous variant; these individuals exhibit motor and/or language delay, ranging from mild to severe, and in one case, epilepsy. Further phenotypic features include varying degrees of intellectual disability, learning difficulties, autism, ADHD, ODD, sleep disorders, and muscular hypotonia. We functionally characterized the four de novo GABBR1 variants, p.Glu368Asp, p.Ala397Val, p.Ala535Thr, and p.Gly673Asp, in transfected HEK293 cells. GABA fails to efficiently activate the variant receptors, most likely leading to an increase in the excitation/inhibition balance in the central nervous system. Variant p.Gly673Asp in transmembrane domain 3 (TMD3) renders the receptor completely inactive, consistent with failure of the receptor to reach the cell surface. p.Glu368Asp is located near the orthosteric binding site and reduces GABA potency and efficacy at the receptor. GABA exhibits normal potency but decreased efficacy at the p.Ala397Val and p.Ala535Thr variants. Functional characterization of GABBR1-related variants provides a rationale for understanding the severity of disease phenotypes and points to possible therapeutic strategies.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a epilepsie $x genetika $7 D004827
- 650 _2
- $a GABA $x metabolismus $7 D005680
- 650 _2
- $a HEK293 buňky $7 D057809
- 650 12
- $a mentální retardace $x genetika $7 D008607
- 650 12
- $a malformace nervového systému $7 D009421
- 650 12
- $a neurovývojové poruchy $x genetika $7 D065886
- 650 12
- $a receptory GABA-B $x genetika $7 D018080
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Stawarski, Michal $u Department of Biomedicine, Pharmazentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland
- 700 1_
- $a Blanc, Xavier $u Medigenome, Swiss Institute of Genomic Medicine, 1207 Geneva, Switzerland
- 700 1_
- $a Nosková, Lenka $u Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Magner, Martin $u Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic; Department of Pediatrics, First Faculty of Medicine, Charles University and University Thomayer Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Platzer, Konrad $u Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany
- 700 1_
- $a Gburek-Augustat, Janina $u Division of Neuropaediatrics, Hospital for Children and Adolescents, University Hospital Leipzig, Leipzig, Germany
- 700 1_
- $a Baldridge, Dustin $u Washington University in St. Louis, St. Louis, MO, USA
- 700 1_
- $a Constantino, John N $u Washington University in St. Louis, St. Louis, MO, USA
- 700 1_
- $a Ranza, Emmanuelle $u Medigenome, Swiss Institute of Genomic Medicine, 1207 Geneva, Switzerland
- 700 1_
- $a Bettler, Bernhard $u Department of Biomedicine, Pharmazentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, Switzerland
- 700 1_
- $a Antonarakis, Stylianos E $u Medigenome, Swiss Institute of Genomic Medicine, 1207 Geneva, Switzerland. Electronic address: stylianos.antonarakis@medigenome.ch
- 773 0_
- $w MED00000254 $t American journal of human genetics $x 1537-6605 $g Roč. 109, č. 10 (2022), s. 1885-1893
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36103875 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151203 $b ABA008
- 999 __
- $a ok $b bmc $g 1891714 $s 1184454
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 109 $c 10 $d 1885-1893 $e 20220913 $i 1537-6605 $m American journal of human genetics $n Am J Hum Genet $x MED00000254
- LZP __
- $a Pubmed-20230120